Results 121 to 130 of about 115,987 (377)

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]

, 2019
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K, Cabrales, Pedro, Lee, Yun Sok, Riopel, Matthew   +3 more
core  

Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study

British Journal of Clinical Pharmacology, 2019
To evaluate the real‐world effect of dipeptidyl peptidase‐4 inhibitor (DPP4i) on the incidence of autoimmune diseases (AD), including rheumatoid arthritis (RA), inflammatory bowel diseases, multiple sclerosis and systemic lupus erythematosus.
Jong-Mi Seong, Jeong Yee, H. Gwak
semanticscholar   +1 more source

Dual‐Functional Food‐Derived Bioactive Peptides: Expanding Beyond Biological Activity

Food Chemistry International, EarlyView.
This review examines recent advances in dual‐ and multifunctional food‐derived bioactive peptides, highlights emerging research integrating biological and techno‐functional properties, and offers perspectives to inform future studies in this field. ABSTRACT Food‐derived bioactive peptides (FBPs) are a diverse group of peptides with proven physiological
Cullen MacDonald, Xiaohong Sun
wiley   +1 more source

Plasma Soluble Dipeptidyl Peptidase-4: A Possible Mechanism for Identifying and Managing Poststroke Cognitive Impairment [PDF]

, 2022
Nadine E. Andrew, Velandai Srikanth
openalex   +1 more source

Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold [PDF]

, 2015
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed.
Biftu T., Borne R. F., Chutian S., Drucker D. J., Drucker D. J., Hawkins P. C. D., Herman G. A., Juillerat-Jeanneret L., Kim D., Nauck M., Occhiato E. G., Orsakov C., Schwehm C., Thomsen I., Thornberry N. A.   +14 more
core   +3 more sources

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

British medical journal, 2018
Objective To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes. Design Population based cohort study.
D. Abrahami, A. Douros, H. Yin, O. Yu, C. Renoux, A. Bitton, L. Azoulay   +6 more
semanticscholar   +1 more source

Insect‐Derived Bioactives for Glycemic Control and Gut Health: A Review

Food Frontiers, EarlyView.
Insect‐derived bioactive compounds (e.g., peptides, polysaccharides) effectively regulate blood glucose through dual mechanisms: directly inhibiting carbohydrate‐digesting enzymes and glucose transporters, and indirectly modulating gut microbiota to enhance intestinal barrier integrity.
Chaoyi Lv, Yuanyuan Huang, Mokhtar Dabbour, Benjamin Kumah Mintah, Ronghai He, Haile Ma   +5 more
wiley   +1 more source

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus [PDF]

, 2021
Xin Wei, Yu Bai, Zhuo Wang, Xiaohong Zheng, Zening Jin, Xin Liu   +5 more
openalex   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

Diabetes, obesity and metabolism, 2017
To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non‐fatal myocardial infarction, non‐fatal
F. Persson, T. Nyström, M. Jørgensen, B. Carstensen, H. Gulseth, M. Thuresson, P. Fenici, D. Nathanson, J. Eriksson, A. Norhammar, J. Bodegård, K. Birkeland   +11 more
semanticscholar   +1 more source